Radiopharmaceuticals for diagnosing Alzheimer's disease

US6676926B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Christoph-Stephan Hilger · Berlin, DE
• Bernd Johannsen · Dresden, DE
• Joerg Steinbach · Bischofswerda, DE
• Peter Maeding · Dresden, DE
• Meredith Halks-Miller · Woodside, US
• Richard Horuk · Belmont, US
• Harald Dinter · San Rafael, US
• Raju Mohan · Encinitas, US
• Joseph E. Hesselgesser · San Francisco, US

Key dates

• Filing date: Nov 6, 2001
• Grant date: Jan 13, 2004
• Expiry date: Nov 6, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/05
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The compounds of formulas (I) and (II) are radiopharmaceuticals that bind to the CCR1 receptor and are able to pass through the blood-brain barrier, and are therefore useful in diagnosing Alzheimer's disease, preferably at an early stage of the disease, wherein X1, X2, R1, R2, R3, R4 and R5 are as defined herein.